FDA authorizes J&J's one-shot coronavirus vaccine

Bio Pharma Dive

The agency's emergency clearance makes J&J's vaccine the third available in the U.S., adding much-needed reinforcements at a critical time

Optimism on Pfizer COVID vaccine is unwarranted

World of DTC Marketing

You need to ask yourself why in the hell Pfizer’s CEO would say that their vaccine is 90% effective when there is a lot more testing and review of data needed. However, there’s still a long way to go before researchers can be certain that this vaccine is indeed as effective as promised.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

The Covid-19 vaccine numbers game

World of DTC Marketing

SUMMARY: The numbers game for COVOD-19 vaccine makers has started but what most of the public, and the media, don’t understand is that the preliminary numbers don’t mean a damn thing until they are peer-reviewed. As I See It COVID Vaccine

Pfizer set to double weekly production of coronavirus vaccine

Bio Pharma Dive

The drugmaker will use production lines at its plant in McPherson, Kansas to help fill vaccine vials, company CEO Albert Bourla said Friday

Covid vaccine profits and the strain on supply channels

World of DTC Marketing

SUMMARY: Pfizer and Moderna will sell $28 billion of Covid-19 vaccines this year. Pharma companies will make an estimated $40 billion on the global COVID-19 vaccine market this year, which will be split between Johnson & Johnson, AstraZeneca, Novavax, and others.

Consumers fall into three COVID-19 vaccine adoption segments

World of DTC Marketing

(Mckinsey) Much of the prevailing market research on COVID-19 vaccination frames sentiment as “likely,” “unlikely,” or “neutral.” Their research has found that consumers’ attitudes towards receiving a COVID-19 vaccine fall into three primary segments. in the news COVID Vaccine

UK authorizes AstraZeneca, Oxford coronavirus vaccine, but questions linger

Bio Pharma Dive

The first public vaccinations with AstraZeneca and Oxford’s shot will begin early in the New Year. But it’s still unclear how effective the vaccine is, or the best way to use it

As COVID-19 becomes a business, vaccine makers confront thorny pricing questions

Bio Pharma Dive

Yearly vaccinations could be required after the pandemic ebbs. Will drugmakers change how they approach pricing their shots

Vaccine makers prepare response as coronavirus mutations raise alarms

Bio Pharma Dive

So far, both Pfizer's and Moderna's vaccines appear to work against more transmissible variants, but preparation is underway for the day they don't

Equitably allocating COVID-19 vaccine

Scienmag

Study sheds light on vaccine acceptance among sexual and gender minorities PHILADELPHIA (March 4, 2021) – Equitable implementation of COVID?19 19 vaccine delivery is a national and global priority, with a strong focus on reducing existing disparities and not creating new disparities. 19 vaccine that […]. But while a framework has been recognized for equitable allocation of COVID?19

Merck stops coronavirus vaccine development in surprise setback

Bio Pharma Dive

The drugmaker, one of the largest vaccine developers globally, won't move forward with either of two candidates it's been testing after disappointing data in early trials

COVID-19 Vaccine Messaging: Why Vaccine Efficacies Can’t Be Compared and Shopped

XTalks

As the US Food and Drug Administration (FDA) handed out an emergency use authorization (EUA) to Janssen’s COVID-19 vaccine over the weekend — making it the third authorized COVID-19 vaccine in the US — many people became laser-focused on the 66 percent average efficacy of the single-dose shot.

Flu Vaccine vs. COVID-19 Vaccine

My Local Study

These differences also explain why vaccines are necessary for both the flu and COVID-19. Read more Flu Vaccine vs. COVID-19 Vaccine. The post Flu Vaccine vs. COVID-19 Vaccine appeared first on MyLocalStudy.com.

COVID-19 vaccine: A hope and prayer?

World of DTC Marketing

QUICK READ : The government is agreeing to pay billions of dollars to the first company that developed a COVID-19 vaccine. billion for 100 million doses of a vaccine made by Pfizer Inc. The question that the media is asking is “will consumers trust a COVID-19 vaccine?”

Coronavirus vaccine from Pfizer, BioNTech prevents COVID-19, early results show

Bio Pharma Dive

An interim analysis conducted after 94 cases of COVID-19 in Pfizer and BioNTech's large study found their vaccine to be more than 90% effective

J&J says single dose of coronavirus vaccine 66% effective in large trial

Bio Pharma Dive

The vaccine's efficacy was higher in the U.S., but lower in Latin America and South Africa, where new, more infectious virus variants are circulating

Trials 276

Novartis joins Sanofi in aiding manufacture of coronavirus vaccines

Bio Pharma Dive

A deal to fill vials of Pfizer and BioNTech's vaccine could be the first of several Novartis signs to help others make COVID-19 treatments

UK to start study testing Pfizer, AstraZeneca vaccines together

Bio Pharma Dive

The government-funded trial will evaluate the effects of mixing vaccines and varying timing between shots

Trials 159

FDA advisers meet to review Pfizer, BioNTech's coronavirus vaccine

Bio Pharma Dive

A panel of vaccine and infectious disease experts will publicly vet the drugmakers' study results on Thursday. Follow the discussion along with BioPharma Dive reporters here

COVID 19 vaccine means big money and greed

World of DTC Marketing

QUICK READ : Pharma had a chance to earn some goodwill with a very skeptical public but it’s become obvious that the rush to develop a vaccine is about profit, executive stock, and Wall Street despite potential huge investments from the government. in the news COVID Vaccine

US secures 200 million more vaccine doses from Pfizer, Moderna

Bio Pharma Dive

would have enough doses to vaccinate 300 million Americans by the end of the July With the orders now finalized, President Biden said the U.S.

Johnson & Johnson Will Test its Vaccine in Infants

NY Times

internal-essential Children and Childhood Coronavirus (2019-nCoV) Drugs (Pharmaceuticals) Immune System Clinical Trials Vaccination and Immunization Babies and Infants Johnson & JohnsonThe company’s coming trials will also involve pregnant women and people whose immune systems are compromised.

Will people line up for a COVID-19 vaccine?

World of DTC Marketing

QUICK READ: As COVID-19 vaccines enter Phase III trials one has to wonder just how transparent pharma companies will be with the data. The rush to develop a COVID-19 vaccine is well underway because there are billions of dollars in profits at stake. As I See It COVID Vaccine

Pfizer, BioNTech's strong results give lift to other coronavirus vaccines

Bio Pharma Dive

But differences between each vaccine could still prove crucial The companies' early success helps validate an industry-wide bet to target the coronavirus' spike protein.

Sanofi, in unusual move, to help Pfizer, BioNTech make coronavirus vaccine doses

Bio Pharma Dive

The French drugmaker, having hit delays with its own coronavirus shot, agreed to manufacture over 100 million doses of Pfizer and BioNTech's vaccine for supply in Europe

Nanoparticle vaccine for COVID-19

Scienmag

Kim focused on developing vaccines for HIV, Ebola and pandemic influenza. But, within days of closing their campus lab space as part of COVID-19 precautions, they turned their attention to a vaccine for SARS-CoV-2, the virus that causes COVID-19.

CanSino, Canada abandon plans for a coronavirus vaccine trial

Bio Pharma Dive

Canada was set to help CanSino produce its experimental shot as part of a deal to run what would've been the country's first coronavirus vaccine study

Trials 282

In milestone, FDA clears coronavirus vaccine from Pfizer, BioNTech for emergency use

Bio Pharma Dive

Vaccinations are expected to begin within days of the historic decision, which follows early approvals in the U.K., Canada and Mexico

AstraZeneca, Oxford vaccine study allowed to restart in UK

Bio Pharma Dive

study participant led to a worldwide pause in vaccinations, the country's drugs regulator and an independent committee allowed testing to resume Six days after a worrisome illness in a U.K.

Vaccine shows signs of protection against dozen-plus flu strains

Scienmag

Medicine & Health Biology Epidemiology Immunology/Allergies/Asthma Infectious/Emerging Diseases Medicine/Health Public Health Vaccines Virology

Vaccine sales driven down by pandemic's effects on doctor visits

Bio Pharma Dive

Pfizer, Sanofi, GSK and Merck each reported lower vaccine sales as stay-at-home orders kept people from their regular vaccinations

Nanoparticle-delivered COVID-19 vaccine candidate shows promise in preclinical studies

Scienmag

According to new findings published in mBio, the vaccine produced potent […]. Nanotechnology Biology Cell Biology Immunology/Allergies/Asthma Infectious/Emerging Diseases Medicine/Health Nanotechnology/Micromachines Vaccines Virology

Pfizer says coronavirus vaccine study still on track for October readout

Bio Pharma Dive

Importantly, the study committee hasn't had reason to pause vaccinations in the trial, something AstraZeneca and the University of Oxford recently reported in tests of their vaccine

Trials 272

FAA says first flight shipping coronavirus vaccine takes off

Bio Pharma Dive

With two experimental shots now undergoing FDA review, airports and shipping companies are readying for the mass shipment of vaccine doses

One and Done: Why People Are Eager for Johnson & Johnson’s Vaccine

NY Times

Johnson & Johnson’s one-shot vaccine is allowing states to rethink distribution, even as health officials and experts worry some will view it as inferior.

Pfizer forecasts $15B sales boost from coronavirus vaccine orders

Bio Pharma Dive

The estimate for 2021 sales, which Pfizer splits with partner BioNTech, would make the vaccine one of the highest-selling medicines in the industry

Sales 158

Moderna gets $1.5B from US for coronavirus vaccine supply

Bio Pharma Dive

has already invested heavily in Moderna's vaccine, having previously committed $1 billion to fund clinical trials and manufacturing scale-up The U.S.

‘Vaccine, vaccine’: Dolly Parton urges Americans to get COVID-19 shots

Pharma Phorum

Efforts to encourage US citizens to take their COVID-19 vaccines received a boost from country music legend Dolly Parton, who updated her hit song “Jolene” to pledge her support in a social media video showing her getting inoculated.

Cyberattacks Discovered on Vaccine Distribution Operations

NY Times

Vaccination and Immunization Cyberwarfare and Defense Computer Security Coronavirus (2019-nCoV) Drugs (Pharmaceuticals) Cybersecurity and Infrastructure Security Agency International Business Machines Corporation Gavi, the Vaccine Alliance Homeland Security Department Pfizer Inc

Pfizer/BioNTech Begin Studies for Third Booster Dose and Development of COVID-19 Vaccine Variants

XTalks

NYSE: PFE ) and BioNTech SE (Nasdaq: BNTX ) have announced that they are beginning a trial to evaluate the safety and efficacy of a third booster dose for their COVID-19 vaccine (BNT162b2), as well as new vaccine variants. Pfizer Inc.

Globally most pregnant women, mothers would get COVID-19 vaccine, vaccinate their children

Scienmag

Acceptance in US and Russia lags Boston, MA–Most pregnant women and mothers of children younger than 18 years old say they would receive a COVID-19 vaccine and vaccinate their children, according to a survey conducted by researchers at Harvard T.H. The research indicated that vaccine acceptance was highest in India, […].

Peer-reviewed report on Moderna COVID-19 vaccine publishes

Scienmag

Data from Phase 3 clinical trial confirm vaccine is effective Credit: NIH WHAT: The investigational vaccine known as mRNA-1273 was 94.1% The vaccine also demonstrated efficacy in preventing severe […].

5 questions ahead of next week's FDA meeting on coronavirus vaccines

Bio Pharma Dive

Normally staid affairs, next Thursday's advisory committee meeting could be historic and set expectations for how the FDA will approach any future vaccine approval